NCSD hosted a webinar on December 9, 2019 that focused on highlights from the Treatment Action Group STI Pipeline Report and offered some key recommendations for STI research advocates.
This webinar will cover some of the exciting new developments in the biomedical research pipeline for testing, prevention, and treatment of gonorrhea, chlamydia, and syphilis. According to the World Health Organization (WHO), in 2016 there were an estimated 376 million new STI cases (roughly 1 million per day). In the United States, rates of gonorrhea, chlamydia, and syphilis are growing at record paces. As STI rates continue to climb, innovation to address this worsening crisis has lagged behind, and new tools are desperately needed.
Earlier this year, Treatment Action Group published the inaugural STI Pipeline Report to identify key opportunities to further biomedical research for STIs and rally community advocates behind this cause. This webinar will focus on highlights from the Pipeline report as well as some key recommendations for STI research advocates.
Introduction by: David C. Harvey, Executive Director, NCSD
Jeffrey Klausner, Professor of Medicine, Division of Infectious Diseases, UCLA
Key Advancements in the Treatment and Prevention of Gonorrhea, Chlamydia, and Syphilis
Barbara Van Der Pol, Associate Professor of Medicine, Division of Infectious Diseases, University of Alabama – Birmingham
Overview of the Diagnostics Pipeline for STIs
Jeremiah Johnson, HIV Project Director, Treatment Action Group
Community Advocacy Priorities for Bacterial STI Research